New hope for Tough-to-Treat lung cancer: major trial tests promising drug combo
NCT ID NCT05184712
Summary
This study is for people with a specific type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) where standard targeted pills have stopped working. It compares a new drug, AK112, combined with two common chemotherapy drugs against the same chemotherapy with a placebo. The goal is to see if adding AK112 can better control the cancer's growth and help patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.